Treatment of tuberculosis: Update 2010

European Respiratory Journal

Volumn 37, Issue 2, 2011, Pages 441-462

  Yew, W W ^a   Lange, C ^c   Leung, C C ^b  

^a GRANTHAM HOSPITAL   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

^c RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Review; Treatment; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PLACEBO; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; BRUCELLOSIS; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH PROGRAM; HOLISTIC CARE; HUMAN; IMMUNOTHERAPY; LEPROSY; LUNG SURGERY; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; QT PROLONGATION; RELAPSE; RETREATMENT; REVIEW; SHORT COURSE THERAPY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MYCOBACTERIUM TUBERCULOSIS; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 79251511858     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00033010     Document Type: Review

References (257)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009.426. Geneva, WHO, 2009.
2. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, WHO, 2010.
3. Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developer's handbook, Annex B. www.sign.ac.uk/guidelines/fulltext/50/annexb.html Date last accessed: April 26, 2010. Date last updated: October 27, 2010.
4. Mitchison D. Basic mechanisms of chemotherapy. Chest 1979; 76: Suppl., 771-781.
5. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005; 171: 699-706. (Pubitemid 40471139)
6. British Thoracic Society. A controlled trial of 6-months' chemotherapy in pulmonary tuberculosis. Final report: Results during the 36-months after the end of chemotherapy and beyond. Br J Dis Chest 1984; 78: 330-336.
7. Singapore Tuberculosis Service/British Medical Research Council. Five year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147-1150.
8. China tuberculosis control collaboration. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
9. Tam CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am J Respir Crit Care Med 1998; 157: 1726-1733.
10. Snider DE Jr, Graczyk J, Bek E, et al. Supervised 6-month treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130: 1091-1094. (Pubitemid 15186171)
11. Third East African/British Medical Research Council Study. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Tubercle 1980; 61: 59-69.
12. Hong Kong Chest Service/British Medical Research Council Study. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. The results up to 24 months. Tubercle 1979; 60: 201-210.
13. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis: a controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; 2: 1102-1104.
14. Slutkin G, Schecter GF, Hopewell PC. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. Am Rev Respir Dis 1988; 138: 1622-1624. (Pubitemid 19005458)
15. Combs DL, O'Brien RJ, Geiter L. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and acceptability: the report of final results. Ann Intern Med 1990; 112: 397-406. (Pubitemid 20098520)
16. World Health Organization. Treatment of tuberculosis. Guidelines, 4th Edn. WHO/HTM/TB/2009.420. Geneva, WHO, 2010.
17. Quy HT, Cobelens FG, Lan NT, et al. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006; 10: 45-51. (Pubitemid 43266276)
18. Yew WW. Chemotherapy including drug-resistant therapy and future developments. In: Davies PDO, Barnes PF, Gordon SB, eds. Clinical Tuberculosis, 4th Edn. London, Hodder Arnold, 2008; pp. 225-242.
19. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251. (Pubitemid 39311345)
20. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
21. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
22. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
23. Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177: 1391-1396. (Pubitemid 351860918)
24. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
25. Chang KC, Leung CC, Yew WW, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170: 1124-1130. (Pubitemid 39488627)
26. Chang KC, Leung CC, Yew WW, et al. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Eur Respir J 2007; 29: 347-351.
27. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995 23, 332: 779-784.
28. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206. (Pubitemid 46855463)
29. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847. (Pubitemid 29251017)
30. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356. (Pubitemid 43209091)
31. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6 vs. a 9-month intermittent treatment regimen in HIV-infected TB patients: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-751.
32. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 2-month, 3-month and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 60 months. Am Rev Respir Dis 1984; 130: 23-28.
33. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 1989; 139: 871-876.
34. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14: 241-242.
35. Kochi A. Is DOTS the health breakthrough of the 1990s? World Health Forum 1997; 18: 225-247.
36. Yew WW. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy 1999; 45: Suppl 2., S26-S33.
37. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1311-1320.
38. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007; 4: CD003343.
39. Rusen ID. Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome. Int J Tuberc Lung Dis 2007; 11: 120-121. (Pubitemid 46219272)
40. Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 2007; 297: 380-386. (Pubitemid 46155799)
41. Mishra P, Hansen EH, Sabroe S, et al. Adherence is associated with the quality of professional-patient interaction in Directly Observed Treatment Short-course DOTS. Patient Educ Couns 2006; 63: 29-37. (Pubitemid 44348862)
42. Newell JN, Baral SC, Pande SB, et al. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006; 367: 903-909.
43. Sbarbaro J, Blomberg B, Chaulet P. Fixed-dose combination formulations for tuberculosis treatment. Int J Tuberc Lung Dis 1999; 3: S286-S288.
44. Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954.
45. Moulding TS, Le HQ, Rikleen D, et al. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampicin. Int J Tuberc Lung Dis 2004; 8: 743-748. (Pubitemid 38747151)
46. World Health Organization. WHO Model List of Essential Drugs www.who.int/medicines/publications/essentialmedicines/en Date last accessed: April 26, 2010. Date last updated: March 2010.
47. A joint statement of the International Union Against Tuberculosis and Lung Disease/and the Tuberculosis Programme of the World Health Organization. The promise and reality of fixed-dose combinations with rifampicin. Tubercle Lung Dis 1994; 75: 180-181.
48. Migliori GB, Raviglione MC, Schaberg T, et al. Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 1999; 14: 978-992.
49. Bartacek A, Schutt D, Panosch B, et al. Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 760-766.
50. Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater®) in the initial phase of chemotherapy in three 6-month regimens for smear positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3: 126-132. (Pubitemid 29151815)
51. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15. (Pubitemid 28108937)
52. Sirgel FA, Fourie PB, Donald PR, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172: 128-135. (Pubitemid 40923325)
53. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51: 2994-2996. (Pubitemid 47206244)
54. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-3788. (Pubitemid 350057771)
55. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009; 10: 381-401.
56. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
57. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
58. Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007; 51: 2546-2551. (Pubitemid 47047335)
59. Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative Trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 879-894.
60. Peloquin C. What is the "right" dose of rifampin? Int J Tuberc Lung Dis 2003; 7: 3-5.
61. African Poverty Related Infection Oriented Research Initiative. Pharmacokinetics and pharmacodynamics of high versus standard dose rifampicin in patients with pulmonary tuberculosis (High RIF). http://clinicaltrials.gov/ct2/ show/NCT00760149 Date last accessed: April 26, 2010. Date last updated: September 25, 2008.
62. Tam CM, Chan SL, Kam KM, et al. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002; 6: 3-10. (Pubitemid 34263539)
63. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360: 528-534.
64. Langdon G, Wilkins JJ, Smith PJ, et al. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004; 8: 862-867. (Pubitemid 38937603)
65. Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004; 169: 1191-1197. (Pubitemid 38680395)
66. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006; 174: 94-101. (Pubitemid 43955249)
67. Rosenthal IM, Zhang M, Williams KN. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4: e344.
68. Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008; 52: 4037-4042.
69. Bock NN, Sterling TR, Hamilton CD, et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002; 165: 1526-1530. (Pubitemid 34606668)
70. Centers for Disease Control and Prevention. TBTC Study 29: rifapentine during intensive phase tuberculosis (TB) treatment. http://clinicaltrials.gov/ ct2/show/NCT00694629 Date last accessed: April 26, 2010. Date last updated: July 13, 2010.
71. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-390.
72. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8: 31-38. (Pubitemid 38120703)
73. Davidson PT. Drug resistance and the selection of therapy for tuberculosis. Am Rev Respir Dis 1987; 136: 255-257.
74. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
75. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430. (Pubitemid 16126276)
76. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644-1650.
77. Li J, Munsiff SS, Driver CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City 1997-2000. Clin Infect Dis 2005; 41: 83-91.
78. Traore H, Fissette K, Bastian I, et al. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 2000; 4: 481-484. (Pubitemid 30256852)
79. Yam WC, Tam CM, Leung CC, et al. Direct detection of rifampin-resistant Mycobacterium tuberculosis in respiratory specimens by PCR-DNA sequencing. J Clin Microbiol 2004; 42: 4438-4443. (Pubitemid 39362352)
80. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545. (Pubitemid 30324196)
81. Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114. (Pubitemid 30123642)
82. Mak A, Thomas A, Del Granado M, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178: 306-312.
83. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO/HTM/TB/2006.361. Geneva, WHO, 2006.
84. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
85. Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: 802-807. (Pubitemid 44031396)
86. Hanif M, Malik S, Dhingra VK. Acquired drug resistance pattern in tuberculosis cases at the State Tuberculosis Centre, Delhi, India. Int J Tuberc Lung Dis 2009; 13: 74-78.
87. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
88. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751. (Pubitemid 30152215)
89. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
90. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980-985. (Pubitemid 46331968)
91. Park SK, Lee WC, Lee DH, et al. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368. (Pubitemid 38624874)
92. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
93. Huang TS, Kunin CM, Shin-Jung Lee S, et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-1062.
94. Park IN, Hong SB, Oh YM, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11: 319-324.
95. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolones resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180: 365-370.
96. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
97. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO/HTM/TB/2008.393. Geneva, WHO, 2008.
98. Dewan P, Sosnovskaja A, Thomsen V, et al. High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002. Int J Tuberc Lung Dis 2005; 9: 170-174.
99. Timperi R, Han LL, Sloutsky A, et al. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis 2005; 9: 175-180. (Pubitemid 40278380)
100. World Health Organization. Guidelines for Drug Susceptibility Testing for Second-line Anti-tuberculosis Drugs for DOTS-plus. WHO/CDS/TB/2001.288. Geneva, WHO, 2001.
101. Drobniewski F, Rusch-Gerdes S, Hoffner S. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF.8.1) - report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 2007; 13: 1144-1156.
102. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569. (Pubitemid 40331189)
103. Kam KM, Sloutsky A, Yip CW, et al. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14: 282-288.
104. Kang YA, Choi YJ, Cho YJ, et al. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology 2006; 11: 793-798. (Pubitemid 44581446)
105. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-Plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 2003; 326: 574.
106. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006; 3: e352.
107. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12: 1389-1397. (Pubitemid 44455215)
108. Bastian I, Rigouts L, Van Deun A, et al. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78: 238-251.
109. Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-976. (Pubitemid 35356618)
110. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837. (Pubitemid 44197841)
111. Mitnick CD, Castro KG, Harrington M, et al. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4: e282.
112. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. WHO/HTM/TB/2008.402. Geneva, WHO, 2008.
113. Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 139-145. (Pubitemid 351212404)
114. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-905.
115. Devasia RA, Blackman A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS, and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63: 1173-1178.
116. Moadebi S, Harder CK, Fitzgerald MJ, et al. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67: 2077-2099. (Pubitemid 47524566)
117. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481. (Pubitemid 37290060)
118. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651. (Pubitemid 39411014)
119. Allen BW, Mitchison DA, Chan YC, et al. Amikacin in the treatment of pulmonary tuberculosis. Tubercle 1983; 64: 111-118. (Pubitemid 13094067)
120. McClatchy JK, Kanes W, Davidson PT, et al. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 1977; 58: 29-34. (Pubitemid 8054011)
121. Jeon DS, Kim DH, Kang HS, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 594-600.
122. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-845.
123. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug-resistant tuberculosis (MDR-TB) - a report of ten cases. J Infect 2006; 52: 92-96. (Pubitemid 43137390)
124. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-704. (Pubitemid 44288145)
125. Boutoille D, Grossi O, Depatureaux A, et al. Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis. Eur J Intern Med 2009; 20: e134-e135.
126. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
127. Centers for Disease Control and Prevention. TBTC S30: Safety and tolerability of low dose linezolid in MDR TB (LiMiT). http://clinicaltrials.gov/ ct2/show/NCT00664313 Date last accessed: April 26, 2010. Date last updated: July 16, 2010.
128. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
129. Yew WW, Chang KC, Chau CH. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 1119.
130. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother 2009; 53: 1314-1319.
131. AstraZeneca. Study to evaluate safety, tolerability and pharmacokinetics (PK) (Including food effect) of oral doses of AZD5847 in healthy volunteers. http://clinicaltrials.gov/ct2/show/NCT01037725 Date last accessed: April 26, 2010. Date last updated: July 13, 2010.
132. Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001; 33: 466-469. (Pubitemid 32611427)
133. Abate G, Miorner H. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxicillin in combination with clavulanic acid and ethambutol. J Antimicrob Chemother 1998; 42: 735-740. (Pubitemid 29008074)
134. Dincer I, Ergin A, Kocagoz T. The in vitro efficacy of β-lactam and β-lactamase inhibitors against multidrug-resistant clinical strains of Mycobacterium tuberculosis. Int J Antimicrob Agents 2004; 23: 408-411. (Pubitemid 38481557)
135. Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025-1026.
136. Yew WW, Wong CF, Lee J, et al. Do β-lactam-β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tuberc Lung Dis 1995; 76: 90-92.
137. Chambers HF, Moreau D, Yajko D, et al. Can penicillins and other β-latam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 1995; 39: 2620-2624.
138. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
139. Hugonnett JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-1218.
140. Holzgrabe U. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis? Chem Med Chem 2009; 4: 1051-1053.
141. Jagannath C, Reddy MV, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083-1086.
142. Matlola NM, Steel HC, Anderson R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J Antimicrob Chemother 2001; 47: 199-202. (Pubitemid 32149528)
143. Janulionis E, Sofer C, Song HY, et al. Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture. Antimicrob Agents Chemother 2004; 48: 3133-3135. (Pubitemid 38989187)
144. Uskudar O, Koksal D, Koksul AS. Partial intestinal obstruction due to clofazimine in a patient with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 703-704. (Pubitemid 40826170)
145. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 1534-1536. (Pubitemid 46586846)
146. Huang TS, Liu YC, Sy CL, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 2008; 52: 2226-2227.
147. Yew WW, Leung CC. Management of multidrug-resistant tuberculosis. Update 2007. Respirology 2008; 13: 21-46.
148. Johnson JL, Hadad DJ, Boon WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-612. (Pubitemid 43845020)
149. Perez-Guzman C, Vargas MH, Martinez-Rossier LA, et al. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2002; 6: 1102-1109. (Pubitemid 36054965)
150. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655. (Pubitemid 32652155)
151. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377. (Pubitemid 43265148)
152. Coyne KM, Pozniak AL, Lamorde M, et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23; 437-446.
153. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
154. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532. (Pubitemid 23053828)
155. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
156. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
157. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884. (Pubitemid 28539469)
158. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174. (Pubitemid 32662125)
159. Drobniewski F, Eltringham I, Graham C, et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002; 57: 810-816. (Pubitemid 34984981)
160. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
161. Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and healthcare workers. Ann Intern Med 1992; 117: 191-196.
162. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514-1521.
163. Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008; 46: 1844-1851.
164. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
165. Cox HS, Kalon S, Alamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS ONE 2007; 2: e1126.
166. Gandhi NR, Shah NS, Andrews JR, et al. HIV co-infection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
167. Kliiman K, Altraja A. Predictors of poor treatment outcome in multidrug- and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085-1094.
168. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
169. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
170. Sotgiu G, Ferrara G, Matteelli MD, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
171. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007; 196: Suppl 1., S28-S34. (Pubitemid 47206082)
172. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426. (Pubitemid 38134824)
173. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170: 1131-1134. (Pubitemid 39488628)
174. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338. (Pubitemid 44156613)
175. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
176. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138. (Pubitemid 351212403)
177. Dorman SE, Johnson JL, Goldsberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
178. Wang JY, Wang JT, Tsai TH, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010; 14: 65-71.
179. University College London. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMox TB). http://clinicaltrials.gov/ct2/show/NCT00864383 Date last accessed: April 26, 2010. Date last updated: March 17, 2009.
180. Rosenthal IM, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis. Am J Respir Crit Care Med 2008; 178: 989-993.
181. Johns Hopkins University. Rifapentine plus moxifloxacin for treatment of pulmonary tuberculosis. http://clinicaltrials.gov/ct2/show/NCT00728507 Date last accessed: April 26, 2010. Date last updated: May 19, 2010.
182. Agrawal D, Udwadia ZF, Rodriguez C, et al. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13: 79-83.
183. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes of extensively drug-resistant tuberculosis in South Africa are poor regardless of HIV status. Lancet 2010; 375: 1798-1807.
184. Cheng AF, Yew WW, Chan EW, et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601. (Pubitemid 38141721)
185. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227. (Pubitemid 40116230)
186. Lounis N, Gevers T, Van Den Berg J, et al. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008; 52: 3568-3572.
187. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007; 51: 1011-1015. (Pubitemid 46355288)
188. Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009; 179: 75-79.
189. Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006; 50: 3543-3547. (Pubitemid 44684863)
190. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC-207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835.
191. Tibotec-Virco Virology BVBA. TMC207-TiDP13-C208: anti-bacterial activity, safety, and tolerability of TMC207 in patients with multidrug-resistant Mycobacterium tuberculosis (MDR-TB). http://clinicaltrials.gov/ct2/show/ NCT00449644 Date last accessed: April 26, 2010. Date last updated: October 18, 2010.
192. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
193. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
194. Otsuka Pharmaceutical Development & Commercialization, Inc. A placebo-controlled, phase 2 trial to evaluate OPC 67683 in patients with pulmonary sputum culture-positive, multidrug-resistant tuberculosis (TB). http://clinicaltrials.gov/ct2/show/NCT00685360 Date last accessed: April 26, 2010. Date last updated: August 18, 2010.
195. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-966. (Pubitemid 30435054)
196. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49: 2289-2293. (Pubitemid 40734456)
197. Tasneen R, Tyagi S, Williams K, et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52: 3664-3668.
198. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52: 1522-1524. (Pubitemid 351522025)
199. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009; 53: 3720-3725.
200. Diacon A, Dawson R, Venter A, et al. Update on PA-824. Int J Tuberc Lung Dis 2008; 12: S14.
201. Hu Y, Coates AR, Mitchison DA. Comparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 69-73.
202. Barry PJ, O'Connor TM. Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem 2007; 14: 2000-2008. (Pubitemid 47209109)
203. Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med 2009; 30: 755-768.
204. Amaral L, Boeree MJ, Gillespie SH, et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now. Int J Antimicrob Agents 2010; 35: 524-526.
205. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 623-625. (Pubitemid 20109149)
206. Sihoe AD, Shiraishi Y, Yew WW. The current role of thoracic surgery in tuberculosis management. Respirology 2009; 14: 954-968.
207. Pomerantz M, Brown JM. Surgery in the treatment of multidrug-resistant tuberculosis. Clin Chest Med 1997; 18: 123-130. (Pubitemid 27152509)
208. Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multidrug resistant tuberculosis. Curr Opin Pulm Med 2006; 12: 179-185. (Pubitemid 44350472)
209. Treasure RL, Seaworth BJ. Current role of surgery in Mycobacterium tuberculosis. Ann Thorac Surg 1995; 59: 1405-1407.
210. van Leuven M, De Groot M, Shean KP, et al. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997; 63: 1368-1372.
211. Sung SW, Kang CH, Kim YT, et al. Surgery increased the chance of cure in multidrug resistant pulmonary tuberculosis. Eur J Cardiothorac Surg 1999; 16: 187-193. (Pubitemid 29376674)
212. Pomerantz BJ, Cleveland JC Jr, Olson HK, et al. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121: 448-453. (Pubitemid 32230212)
213. Chiang CY, Yu MC, Bai KJ, et al. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int J Tuberc Lung Dis 2001; 5: 272-277.
214. Park SK, Lee CM, Heu JP, et al. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002; 6: 143-439.
215. Naidoo R, Reddi A. Lung resection for multidrug-resistant tuberculosis. Asian Cardiovasc Thorac Ann 2005; 13: 172-174. (Pubitemid 40852194)
216. Takeda S, Maeda H, Hayakawa M, et al. Current surgical intervention for pulmonary tuberculosis. Ann Thorac Surg 2005; 79: 959-963. (Pubitemid 40288755)
217. Kir A, Inci I, Torun T, et al. Adjunctive resectional surgery improves cure rates in multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2006; 131: 693-696.
218. Somocurcio JG, Sotomayor A, Shin S, et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 2007; 62: 416-421. (Pubitemid 46698391)
219. Kim HJ, Kang CH, Kim YT, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006; 28: 576-580. (Pubitemid 44794673)
220. Mohsen T, Zeid AA, Haj-Yahia S. Lobectomy or pneumonectomy for multidrug-resistant pulmonary tuberculosis can be performed with acceptable morbidity and mortality: a seven-year review of a single institution's experience. J Thorac Cardiovasc Surg 2007; 134: 194-198. (Pubitemid 46962057)
221. Wang H, Lin H, Jiang G. Pulmonary resection in the treatment of multidrug-resistant tuberculosis: a retrospective study of 56 cases. Ann Thorac Surg 2008; 86: 1640-1645.
222. Shiraishi Y, Katsuragi N, Kita H, et al. Aggressive surgical treatment of multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2009; 138: 1180-1184.
223. Griffith DE. Treatment of multidrug-resistant tuberculosis. Should you try this at home? Am J Respir Crit Care Med 2004; 169: 1082-1083.
224. Torun T, Tahaoglu K, Ozmen I, et al. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2007; 11: 979-985. (Pubitemid 47425024)
225. Park SK, Kim JH, Kang H, et al. Pulmonary resection combined with rifampin-based drug therapy for patients with multidrugresistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2009; 13: 170-175.
226. Kwon YS, Kim YH, Suh GY, et al. Treatment outcomes for HIVuninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
227. Dravniece G, Cain KP, Holtz TH, et al. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J 2009; 34: 180-183.
228. Shiraishi Y, Katsuragi N, Kita H, et al. Experience with pulmonary resection for extensively drug-resistant tuberculosis. Interact Cardiovasc Thorac Surg 2008; 7: 1075-1078.
229. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-1082.
230. Naidoo R. Surgery for pulmonary tuberculosis. Curr Opin Pulm Med 2008; 14: 254-259. (Pubitemid 351572328)
231. Dewan RK, Singh S, Kumar A, et al. Thoracoplasty: an obsolete procedure? Indian J Chest Dis Allied Sci 1999; 41: 83-88.
232. Jouveshomme S, Dautzenberg B, Bakdach H, et al. Preliminary results of collapse therapy with plombage for pulmonary disease caused by multidrug-resistant mycobacteria. Am J Respir Crit Care Med 1998; 157: 1609-1615.
233. Motus IY, Skorniakov SN, Sokolov VA, et al. Reviving an old idea: can artificial pneumonthorax play a role in the modern management of tuberculosis? Int J Tuberc Lung Dis 2006; 10: 571-577.
234. Jouanguy E, Doffinger R, Dupuis S, et al. IL-12 and IFN-γ in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11: 346-351.
235. Sugawara I, Yamada H, Kaneko H, et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999; 67: 2585-2589. (Pubitemid 29200522)
236. Fortes A, Pereira K, Antas PR, et al. Detection of in vitro interferon-γ and serum tumour necrosis factor-α in multidrug-resistant tuberculosis patients. Clin Exp Immunol 2005; 141: 541-548. (Pubitemid 41075879)
237. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 2007; 7: 327-337. (Pubitemid 46767790)
238. Churchyard GJ, Kaplan G, Fallows D, et al. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009; 30: 769-782.
239. Mayosi BM, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2000; 2: CD000526.
240. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; 1: CD002244.
241. Matchaba PT, Volmink J. Steroids for treating tuberculous pleurisy. Cochrane Database Syst Rev 2000; 2: CD001876.
242. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
243. Elliott AM, Luzze H, Quigley MA, et al. A randomized double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-associated pleural tuberculosis. J Infect Dis 2004; 190: 869-878. (Pubitemid 39120962)
244. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191: 856-865. (Pubitemid 40349799)
245. Condos R, Schluger NW. Cytokine-based approaches to the treatment of multidrug-resistant tuberculosis. Bio Drugs 1999; 11: 165-173. (Pubitemid 29146969)
246. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 1997; 349: 1513-1515. (Pubitemid 27216363)
247. Johnson BJ, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug-resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997; 78: 195-203. (Pubitemid 28256669)
248. Palmero D, Eiguchi K, Rendo P, et al. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999; 3: 214-218. (Pubitemid 29133046)
249. Giosue S, Casarini M, Ameglio F, et al. Aerosolized interferon-α treatment in patients with multidrug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000; 11: 99-104.
250. Grahmann PR, Braun RK. A new protocol for multiple inhalation of IFN-γ successfully treats MDR-TB: a case study. Int J Tuberc Lung Dis 2008; 12: 636-644. (Pubitemid 351846761)
251. Park SK, Cho S, Lee IH, et al. Subcutaneously administered inferferon-γ for the treatment of multidrug-resistant pulmonary tuberculosis. Int J Infect Dis 2007; 11: 434-440. (Pubitemid 47239452)
252. Stanford JL, Stanford CA, Grange JM, et al. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multidrug-resistant pulmonary tuberculosis? Respir Med 2001; 95: 444-447.
253. Dawson R, Condos R, Tse D, et al. Immunomodulation with recombinant interferon-γ1b in pulmonary tuberculosis. PLoS One 2009; 4: e6984.
254. Ralph AP, Kelly PM, Anstey NM. L-arginine and vitamin D: novel adjunctive immunotherapies. Trends Microbiol 2008; 16: 336-344.
255. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized placebo-controlled trial. Am J Respir Crit Care Med 2009; 179: 843-850.
256. Martins M, Viveiros M, Couto I, et al. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. Int J Tuberc Lung Dis 2009; 13: 569-573.
257. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.